Decades of History Tell Anything: Biotech Near $50 Set to Soar
A cash-generative biotech near $50 is drawing buyers amid a market shift toward defensible healthcare names. Here’s w...
Understanding when it's too late to start a retirement plan is crucial for your financial health. This article provides insights to help you assess your situation.
22,641 articlesA cash-generative biotech near $50 is drawing buyers amid a market shift toward defensible healthcare names. Here’s w...
A new wave of weight-loss therapies aims to beat current GLP-1 drugs by reducing side effects and daily dosing. Inves...
SPHY has delivered monthly income since 2012, but 2026 tests whether its high-yield payout can withstand cyclical str...
Vertex Pharmaceuticals just made aBold move that could reshape its growth trajectory. This guide breaks down the deal...
US search interest in Bitcoin has surged to a five-year high even as prices remain in a bear market. Traders watch wh...
Airports face ongoing delays as spring travel returns. Enrolling in TSA PreCheck may help speed security lines for ti...
Bitcoin struggles to clear the $90K barrier as four market forces converge. Analysts say a sustained weekly close abo...
Pfizer stock hovers around the $26 level as insiders aren’t buying Pfizer stock. Analysts point to a patient, value-f...
Zcash has finalized the Ironwood upgrade to patch a vulnerability in the Orchard pool, with activation targeted for l...
At midyear 2026, JPMorgan’s top three overweight picks show a split: one stock has cleared its upside target, while t...
Jim Cramer argues that Google could win the AI war by leveraging Apple’s massive device base, a move that could redef...
Bitcoin faces renewed scrutiny as gold climbs and crypto markets wobble in early 2026, challenging the widely watched...